PHARMA News & Analysis

All but a couple of shares in this industry have sold off. Our analysts think these three high quality companies have fallen too far. 

Eli Lilly and Novo Nordisk have staged big rallies. Here’s how investors can approach this potentially huge opportunity.

The legalisation of cannabis in Canada has boosted an industry that Morningstar forecasts will grow by nine times through 2030

These companies are each trading at prices substantially below Morningstar analysts' fair value estimates and with projected earnings-per-share...

Mayne Pharma has slipped to an impairment-driven half-year loss of $174.2m but says that after experiencing challenging conditions over the past...

Vaccines and blood products supplier CSL's half-year net profit has surpassed $US1bn for the first time, partly due to a big lift in sales of flu...

Australian Pharmaceutical Industries says the time is right to seek health and beauty acquisitions that build on its retail operations such as...